Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Solid Tumor × Ipilimumab × Clear all

Phase

Status

Withdrawn 1 Recruiting 1 Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Melanoma 13 Uterine Cervical Neoplasms 2 Prostatic Neoplasms 2 Neoplasm Metastasis 2 Hematologic Neoplasms 2 Colorectal Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Xeroderma Pigmentosum 1 Vulvar Neoplasms 1 Vaginal Neoplasms 1 Uveal Melanoma 1 Turcot syndrome 1 Triple Negative Breast Neoplasms 1 Solid Tumor 1 Sarcoma 1 Neuroblastoma 1 Multiple Myeloma 1 Lymphoma 1 Lymphatic Metastasis 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Hemangiosarcoma 1 Esophageal Neoplasms 1 Colorectal Neoplasms, Hereditary Nonpolyposis 1 Colonic Neoplasms 1 Central Nervous System Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Merkel Cell 1 Carcinoma 1 Breast Neoplasms 1

Interventions

vistusertib 2 toripalimab 1 tanespimycin 1 sargramostim 1 roniciclib 1 abemaciclib 1 Letrozole 1 Ipilimumab 1 Hydroxychloroquine 1 Fulvestrant 1 Anastrozole 1 Albumin-Bound Paclitaxel 1 AMG 337 1 4-toluenesulfonamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05284214 2023-09-15

SALIENT

Partner Therapeutics, Inc.

Phase 2 Withdrawn

Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡